

5th ATTR

International
Amyloidosis
Meeting
for Patients
and Doctors

**25-26
SEPTEMBER 2025**

Baveno (VB)
ITALY



5th International Amyloidosis Meeting for Patients and Doctors

PROGRAMME FOR DOCTORS



ORGANIZED BY



In collaboration with

PAVIA AMYLOIDOSIS RESEARCH AND TREATMENT CENTER



Fondazione IRCCS
Policlinico San Matteo

Sistema Socio Sanitario



Regione
Lombardia



Under the Auspices of





SCIENTIFIC COMMITTEE

Fabian AUS DEM SIEPEN

Clinic for Cardiology Heidelberg University Hospital, Heidelberg, Germany

Catilena Bibiloni

President ABEA Amyloidosis Association Balearic Islands, Spain

Isabel Conceição

Department of Neurology National Hereditary Amyloidosis Reference Center, ULS Santa Maria, CAML, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

Giovanni D'Alessio

President of the Amyloidosis Alliance and Treasurer fAMY Association, Milano, Italy

Thibaud Damy

Referral Center for Cardiac Amyloidosis, Department of Cardiology, University Hospital Henri Mondor, Creteil, France

Elisabetta Durini

Secretary fAMY Association, Bologna, Italy

Andoni Echaniz-Laguna

Neurology Department Bicêtre University Hospital, Paris, France

Agnes Farrugia

Amyloidosis Alliance Past Executive Director, Paris, France

Pablo Garcia-Pavia

Cardiology Unit, Hospital Universitario Puerta De Hierro, Madrid, Spain

Julian Gillmore

National Amyloidosis Centre, UCL, Royal Free Hospital, London, UK

David Gregory

Amyloidosis Alliance - Board Member / Treasurer And Amyloidosis UK - Trustee / Secretary

Laura Obici

Rare Diseases Unit and Amyloidosis Research and Treatment Center, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy

Márcia Waddington

Federal University of Rio De Janeiro and Complexo Hospital Américas Samaritano-Vitória Barra, Rio De Janeiro, Brazil



FACULTY

Nicoletta Balbo, Milano (ITALY)
Aina Isabel Gaya Barroso, Palma de Mallorca (SPAIN)
Vittorio Bellotti, Pavia, (ITALY)
Catilena Bibiloni, Palma de Mallorca (SPAIN)
Diana Bonderman, Wien (AUSTRIA)
Chiara Briani, Padova (ITALY)
Rosaline Callaghan, Derry (IRELAND)
Francesco Cappelli, Firenze (ITALY)
Maria Cappello, Palermo (ITALY)
Anne Marie Carr, Ontario (CANADA)
Christine Chiti, London (UK)
Jaime Christmas, Auckland (NEW ZEALAND)
Alberto Cipriani, Padova (ITALY)
Eugenia Cisneros-Barroso, Palma de Mallorca (SPAIN)
Isabel Conceicao, Lisboa (PORTUGAL)
Giovanni D'Alessio, Milan (ITALY)
Thibaud Damy, Creteil (FRANCE)
Keith Dares, CANADA
Emily Dixon, London (UK)
Elisabetta Durini, Bologna (ITALY)
Andoni Echaniz-Laguna, Paris (FRANCE)
Agnes Farrugia, Paris (FRANCE)
Jean Christophe Fidalgo, Gemenos (FRANCE)
Marianna Fontana, London (UK)
Lucia Galan, Madrid (SPAIN)
Pablo Garcia-Pavia, Madrid (SPAIN)
Gabriella Gervasi, Viterbo (ITALY)
Julian Gillmore, London (UK)
Juan Gonzalez- Moreno, Palma de Mallorca (SPAIN)
David Gregory, Shrewsbury (UK)
Susan Gregory, Shrewsbury (UK)
Pietro Guaraldi, Bologna (ITALY)
Bouke Hazenberg, Groningen (THE NETHERLANDS)
Celine Labeyrie, Le Kremlin-Bicetre (FRANCE)
Olivier Lairez, Toulouse (FRANCE)

Francesca Lavatelli, Pavia (ITALY)
Alan Levi, Salisbury (UK)
Ines Limon Romero, Valverde Del Camino (SPAIN)
Simone Longhi, Bologna (ITALY)
Marco Luigetti, Roma (ITALY)
Lionel Martinez, Paris (FRANCE)
Steven Maupou, Creteil (FRANCE)
Mario Melazzini, Milano (ITALY)
Giampaolo Merlini, Pavia (ITALY)
Paolo Milani, Pavia (ITALY)
Angelo Minnella, Roma (ITALY)
William Moody, Birmingham (UK)
Roberta Mussinelli, Pavia (ITALY)
Vincent Nicholas, Salisbury (UK)
Hans Nienhuis, Groningen (THE NETHERLANDS)
Laura Obici, Pavia (ITALY)
Giovanni Palladini, Pavia (ITALY)
Milena Paneque Herrera, Porto (PORTUGAL)
Amanda Peltier, Nashville (USA)
Ricardo Pereira E Silva, Lisboa (PORTUGAL)
Stefano Perlini, Pavia (ITALY)
Violaine Plante-Bordeneuve, Creteil (FRANCE)
Otavio Rizzi Coelho Filho, Campinas (BRAZIL)
Christoph Roecken, Kiel (GERMANY)
Lorena Saelices Gomez, Dallas (USA)
Manuel Sanchez, Paris (FRANCE)
Giulia Sandoli, Pavia (ITALY)
Gianfranco Sinagra, Trieste (ITALY)
Martina Smorti, Pisa (ITALY)
Scott Solomon, Boston (USA)
Luisa Sousa, Sta Maria Da Feira (PORTUGAL)
Dominique Thirry, Saint Just (FRANCE)
Marcus Vinicius-Simões, Ribeirão Preto (BRAZIL)
Marcia Waddington-Cruz, Rio de Janeiro (BRASIL)
Jonas Wixner, Umea (SWEDEN)



SCIENTIFIC PROGRAMME

PROGRAMME FOR DOCTORS

THURSDAY, 25 SEPTEMBER 2025

ROOM CARLO 2

07.30-18.30	Secretariat Opening Hours and Registrations
08.15-08.25	Welcome Address Laura Obici (Italy)
08.25-08.45	Greetings from the Authorities
08.45-09.40	SESSION 1 DISEASE HETEROGENEITY: BRIDGING MOLECULAR EVIDENCE TO CLINICAL FEATURES <i>Chairs:</i> Bouke Hazenberg (The Netherlands), Francesca Lavatelli (Italy)
08.45-09.05	Structural and composition heterogeneity of amyloid and development of new biomarkers Lorena Saelices (USA)
09.05-09.25	One pathogenic protein dealing with a million of interactors Christoph Roeken (Germany)
09.25-09.40	Discussion
09.40-10.25	Where evidence meets action: the role of data in ATTR cardiomyopathy clinical decision-making <i>This symposium is sponsored by PFIZER</i> <i>Chair:</i> Francesco Cappelli (Italy)
09.40-09.50	ATTR amyloidosis: do wild-type and hereditary ATTR cardiomyopathy require the same approach? Francesco Cappelli (Italy)
09.50-10.10	Elevating clinical decision making: the role of robust data in guiding the treatment of ATTR cardiomyopathy Pablo Garcia-Pavia (Spain)
10.10-10.20	Putting our knowledge into practice: clinical cases in ATTR cardiomyopathy Francesco Cappelli (Italy)
10.20-10.25	Questions and Answers
10.25-10.45	COFFEE BREAK



PROGRAMME FOR DOCTORS

THURSDAY, 25 SEPTEMBER 2025

ROOM CARLO 2

10.45-11.10	LECTURE Research at the heart of patient care: A personal journey <i>chair:</i> Laura Obici (Italy) Giampaolo Merlini (Italy)
11.10-12.25	SESSION 2 ATTR AMYLOIDOSIS: ADVANCES IN DIAGNOSIS AND DISEASE MONITORING <i>Chairs:</i> Isabel Conceicao (Portugal), Marcus Vinicius Simões (Brazil)
11.10-11.25	State of the art Andoni Echaniz-Laguna (France)
11.25-12.25	ORAL COMMUNICATIONS
11.25-11.37	Transthyretin as a Biomarker in Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy: Insights into Disease Progression Bernardo Machado Antunes, <u>Catarina Falcão de Campos</u> , Mamede de Carvalho, Isabel Conceição
11.37-11.49	Unmasking amyloidosis in lumbar stenosis <u>Loïc Van Oost</u> , Karel Willems, Karl Dujardin, Arne Decramer
11.49-12.01	Serum neurofilament light chain in relation to autonomic neuropathy in hereditary transthyretin amyloidosis <u>Milou Berends</u> , Anne Floor Brunger, Hendrea S.A. Tingen, Johan Bijzet, Charlotte E. Teunissen, Paul A. van der Zwaag, Reinold O.B. Gansa, Bouke P.C. Hazenberg, Fiete Lange, Gea Drost, Walter Noordzij, Hans L.A. Nienhuis, Riemer H.J.A. Slart
12.01-12.13	Cardiac phenotype in hereditary transthyretin amyloidosis: Correlation between fibril types and 99mTc-DPD uptake <u>Viktor Löfbacka</u> , Jonas Wixner, Justina Damjanovic Vesterlund, Per Westermark, Intissar Anan, Björn Pilebro
12.13-12.25	Fast-tracking Transthyretin cardiac amyloidosis detection from 12-lead ECG: Validating the deep learning model Willem Esther González-López, François De Guio, Mariana Brandão, Lucía Perard, Nerea Mora-Ayestaran, Ruben Abbou, Rafael López García, Ángel de la Linde Valdés, Víctor Valdés, Iñigo Sánchez Rodríguez, Rubén Ruiz Zamorano, José María Lillo-Castellano, Manuel Marina-Breyse, <u>Pablo García-Pavía</u>



PROGRAMME FOR DOCTORS

THURSDAY, 25 SEPTEMBER 2025

ROOM CARLO 2

12.25-13.10	The Heart of the MATTer: A time for change in ATTR-CM <i>This symposium is sponsored by BAYER</i> <i>Chair: Gianfranco Sinagra (Italy)</i>
12.25-12.30	ATTR-CM: A time for change Gianfranco Sinagra (Italy)
12.30-12.45	Diagnosing ATTR-CM: From complexity to clarity Olivier Lairez (France)
12.45-13.00	Treating ATTR-CM: From pathophysiology to practice Marianna Fontana (UK)
13.00-13.10	Questions and Answers
13.10-14.15	LUNCH BREAK

ROOM GALASSIA

13.30-14.15	Moderated ePOSTER PRESENTATION
	GROUP 1 Epidemiology and Genetics <i>Chair: Amanda Peltier (USA)</i>
13.30-13.36	Evolving trends in hereditary ATTR amyloidosis: an analysis of the retrospective cohort CARDINAL study in Portugal Catarina Falcão de Campos , Diogo Pereira, Marisa Pardal, Margarida Lopes, Rui Cortes, Carolina Ferraz, João Couceiro, Filipa Bernardo, Teresa Coelho, Isabel Conceição
13.36-13.42	Unraveling the genetic landscape of transthyretin amyloidosis in the Balearic Islands: evidence for a unique founder effect Eugenia Cisneros Barroso , Marc Ventayol-Guirado, Cristina Descals, Joan Carles Montalà, Jorge Álvarez-Rubio, Jéssica Hernández Rodríguez, José Manuel Lustre Rodríguez, María Victoria Llull-Albertí, Juan Antonio Jiménez-Barceló, Víctor Asensio-Landa, Laura Torres Juan, Iciar Martínez López, María Antonia Ribot-Sanso, Juan Buades Reinés, Damià Heine Suñer, Juan Gonzalez Moreno, Inés Losada, Tomás Ripoll-Vera, Jaume Pons, Elena Fortuny, Teresa Bosch, Antoni Figuerola



PROGRAMME FOR DOCTORS

THURSDAY, 25 SEPTEMBER 2025

ROOM GALASSIA

13:42-13:48	Analysis of hereditary transthyretin amyloidosis: clinical differentiation and genetic characterization of 5,000 screened cases in Germany, Austria, and Switzerland Filipa Curado, Sabine Roesner, Tobias Boettcher, <u>Paulo Braga</u>, Joerg Rennecke, Daniel Schulze, Victor Llineares, Peter Bauer
13:48- 13:54	Lower mitochondrial DNA copy number in Swedish carriers of hereditary transthyretin amyloidosis <u>Gabriella Johansson</u>, Malin Olsson, Marina Rubio Garcia, Anders Olofsson, Intissar
13:54-14:00	Characteristics, treatment patterns, and outcomes of patients with hereditary transthyretin amyloidosis: an observational, retrospective study in China (OverTTuRe China) Zhuang Tian, Lingchao Meng, Wei Ma, Daoquan Peng, Yugang Dong, Jiangtao Yan, Qing Zhang, Di Lu, Shaosen Zhang, Krister Järbrink, <u>Jason Wright</u>
14:00-14:06	Transthyretin amyloid cardiomyopathy in a southeast Asian population <u>Weixian Alex Tan</u>, Zhen Wei Teo, Iswaree Devi D/O Balakrishnan, Shaw Yang Chia, Hak Chiaw Tang, Chun Yuan Khoo
14:06-14:12	Hereditary transthyretin amyloidosis: inheritance pattern and disease phenotype within the Swedish population <u>Camilla Carlström</u>, Sandra Arvidsson, Intissar Anan, Victoria Heldestad
GROUP 2 Neurological markers for early diagnosis and disease progression <i>Chair: Chiara Briani (Italy)</i>	
13:30-13:36	Neurophysiological insights in ATTR hereditary amyloidosis with neuropathy: early markers <u>Isabel Conceição</u>, Isabel De Castro, Catarina Falcão de Campos, Juan Gonzalez-Moreno, Ines Losada, José Castro
13:36-13:42	Clinical and neurophysiological correlates of neuropathic pain in ATTRv amyloidosis with neuropathy <u>Isabel Conceição</u>, Jose Castro
13:42-13:48	Estimating meaningful differences in measures of autonomic symptom impairment and overall disability in patients with hereditary transthyretin amyloidosis with polyneuropathy <u>Márcia Waddington-Cruz</u>, John Berk, Teresa Coelho, Isabel Conceição, Morie Gertz, Julian D. Gillmore, Sami Khella, Ahmad Masri, Mathew Maurer, Laura Obici, Jonas Wixner, T. Jesse Kwok, Jonatan Nåtman, Barry Reicher, Folke Folkvaljon



PROGRAMME FOR DOCTORS

THURSDAY, 25 SEPTEMBER 2025

ROOM GALASSIA

13:48- 13:54	Vagal nerve ultrasound in Swedish patients with hereditary V30M transthyretin amyloidosis: a pilot study in late-onset cases Karin Rendahl, Sandra Arvidsson, Intissar Anan, <u>Victoria Heldestad</u>
13:54-14:00	Therapeutic challenges in ATTRv neuropathy: the need for early prediction of treatment failure <u>Isabel Conceicao</u> , Isabel Castro, Catarina Falcão de Campos, Juan Gonzalez Moreno, Inês Losada, José Castro
14:00-14:06	Early six-month quantitative assessment predicts neurological conversion risk in asymptomatic ATTRv carriers <u>Lucia Galan Davila</u> , Laura Martinez Vicente, Alejandro Horga, Nicolas Rodriguez Albacete, Antonio Guerrero Sola, Maria Fenollar Cortes, Alejandra Restrepo Cordoba, Pablo Garcia-Pavia
14:06-14:12	A real-world study of health-related quality of life among patients with transthyretin amyloidosis with polyneuropathy <u>Klas Rikner</u> , Gengshi Chen, Mia Papas, Susan Grandy, Jack Wright, Jade Garratt-Wheelodon
GROUP 3 Treatment <i>Chair: Violaine Planté-Bordeneuve (France)</i>	
13:30-13:36	Silence Project: use of transthyretin silencers in real clinical practice in variant transthyretin amyloidosis (ATTRv) in Spain Ines Losada López, <u>Juan González-Moreno</u> , Cristina Bayón González, Adrian Rodriguez Rodriguez, Fernando Martínez Valle, Aida Alejandre Monforte, Carlos Casasnovas Font, Solange Kapetanovic, Roberto Fernández Torró
13:36-13:42	In patients treated with acoramidis, addition of concomitant tafamidis does not further increase serum TTR levels Mathew S. Maurer, Francesco Cappelli, <u>Marianna Fontana</u> , Pablo Garcia-Pavia, Martha Grogan, Mazen Hanna, Daniel P. Judge, Ahmad Masri, Nitasha Sarswat, Jing Du, Suresh Siddhanti, Jean-François Tamby, Alan X. Ji, Uma Sinha, Jonathan C. Fox, Julian D. Gillmore
13:42-13:48	Acoramidis improves serum TTR levels in patients with wild-type or variant transthyretin amyloid cardiomyopathy Margot K. Davis, <u>Kevin M. Alexander</u> , Amrut Ambardekar, Daniel P. Judge, Deirdre Mooney, Leonardo Bolognese, Michel G. Khouri, Richard K. Cheng, Richard Wright, Robert Gordon, Jing Du, Suresh Siddhanti, Jean-François Tamby, Jonathan C. Fox, Alan X. Ji, Uma Sinha, Julian D. Gillmore, Mathew S. Maurer



PROGRAMME FOR DOCTORS

THURSDAY, 25 SEPTEMBER 2025

ROOM GALASSIA

13:48- 13:54	Eplontersen slows disability progression and deterioration of gait speed in patients with hereditary transthyretin amyloidosis with polyneuropathy Michael Polydefkis, John Berk, Teresa Coelho, Morie Gertz, Sami Khella, Ahmad Masri, Mathew Maurer, Markus Weiler, <u>Jonas Wixner</u>, T. Jesse Kwok, Jonatan Nåtman, Maksym Pola, Márcia Waddington-Cruz
13:54-14:00	Effectiveness and safety of diflunisal in Transthyretin Amyloidosis (ATTR) <u>Juan Gonzalez-Moreno</u>, Ines Losada López, Maria Antonia Ribot Sansó, Paula Hernandez Sanjuan, Cristina Bayon Gonzalez, Eugenia Cisneros Barroso
14:00-14:06	Experience with vutrisiran in ATTRv neuropathy in a single non endemic center <u>Nicolás Rodríguez Albacete</u>, Laura Martínez Vicente, Alejandro Horga Hernández, Antonio Guerrero Sola, Gerardo Gutiérrez Gutiérrez, Ángel Guerrero Peral, Alejandra Restrepo-Córdoba, Jennifer Morata Bianchi, Pablo García-Pavía, Lucía Galán Dávila
14:06-14:12	Acoramidis treatment is associated with a lower incidence of atrial fibrillation/atrial flutter events in patients with ATTR-CM: post-hoc analyses of the ATTRIBUTE-CM trial <u>Kevin M. Alexander</u>, Laura Obici, Steen Hvitfeldt Poulsen, Mathew S. Maurer, James L. Januzzi, Brett Sperry, Wael Jaber, Jing Du, Kai Vogtländer, Adam Castaño, Jean-François Tamby, Jonathan C. Fox, Sumeet Mitter, Mazen Hanna, Ronald Witteles
GROUP 4 Markers for early diagnosis and progression in ATTR-CM <i>Chair: Bjorn Pilebro (Sweden)</i>	
13:30-13:36	Sex differences in hospitalizations among patients with transthyretin amyloid cardiomyopathy in the 6 months before diagnosis: insights from the Nationwide Readmission Database Chun Shing Kwok, Adnan I Qureshi, Richard P Steeds, Gregg C Fonarow, Biykem Bozkurt, Marianna Fontana, Julian D Gillmore, <u>William E Moody</u>
13:36-13:42	Acoramidis-mediated early increase in serum transthyretin level reduces cardiovascular-related hospitalizations and mortality: insights from the ATTRIBUTE-CM study Nitasha Sarswat, Amrut Ambardekar, Jorg Taubel, Justin L. Grodin, Julian D. Gillmore, Matthias Dupont, Richard Wright, Jing Du, Suresh Siddhanti, Jean-François Tamby, Alan X. Ji, Uma Sinha, Jonathan C. Fox, <u>Nagihan Turgut</u>, Mathew S. Maurer, Richard K. Cheng



PROGRAMME FOR DOCTORS

THURSDAY, 25 SEPTEMBER 2025

ROOM GALASSIA

13:42-13:48	Musculoskeletal comorbidities as early presentation in transthyretin amyloidosis: a systematic review and development of a tool for early diagnosis <u>Dries Dewulf</u>, Ilse Degreef, Arne Decramer
13:48- 13:54	Risk of newly occurring polyneuropathy (PN) in patients diagnosed with amyloid transthyretin cardiomyopathy (ATTR-CM) <u>Christoph Ohlmeier</u>, Dominik Obermüller, Dennis Häckl, Thomas Evers, Craig I. Coleman
13:54-14:00	Temporal evolution of transthyretin cardiac amyloidosis phenotypes on cardiac magnetic resonance <u>Giulio Sinigiani</u>, Laura De Michieli, Martina Perazzolo Marra, Domenico Corrado, Alberto Cipriani
14:06-14:12	Validation of an algorithm to identify patients with amyloid transthyretin cardiomyopathy (ATTR-CM) in linked real-world data from the Netherlands – the ValidATTR study <u>Peter-Paul Zwetsloot</u>, Christian Knackstedt, Christoph Ohlmeier, Thomas Evers, Eleonora Iob, Abigail Postema, Naomi Reimes, Priya Narayan, Ilona Verburg, Jetty Overbeek, Nikita Jeswani, Arjan Diepstra, Michelle Michels, Marish Oerlemans
GROUP 5 Ongoing new studies <i>Chair: Diana Bonderman (Austria)</i>	
13:30-13:36	ACO-REAL – a non-interventional study providing insights into the use of acoramidis in people with transthyretin amyloid cardiomyopathy in routine clinical practice <u>Marianna Fontana</u>, Francesco Cappelli, Julian Gillmore, Laura Obici, Fabian Siepen, Philippe Debonnaire, Esther Gonzalez-Lopez, Martin Merz, Antonio Ciaccia, Pablo Garcia-Pavia
13:36-13:42	MaesTTRo: Initial experience from a prospective, non-interventional, multi-country study of patients with amyloid transthyretin amyloidosis Martha Grogan, Margot K. Davis, Katrin Hahn, Ahmad Masri, Jason Wright, Eric Wittbrodt, Anna-Karin Sundin, Jonatan Nätman, <u>Julian D. Gillmore</u>
13:42-13:48	An interventional pilot study on the feasibility and acceptance of a psychological support program for patients, caregivers, and presymptomatic carriers in hereditary transthyretin amyloidosis Giulia Sandoli, <u>Roberta Mussinelli</u>, Alessandro Lozza, Mario Nuvolone, Eleonora Di Buduo, Celeste Poma, Martina Botteri, Luca Filighera, Giovanni Palladini, Damiano Rizzi, Laura Obici



PROGRAMME FOR DOCTORS

THURSDAY, 25 SEPTEMBER 2025

ROOM GALASSIA

13:48- 13:54	Real-world post-diagnosis treatment patterns and outcomes in patients with ATTR amyloidosis: Results from the multi-country OverTTuRe study <u>Pablo Garcia-Pavia</u> , Zhuang Tian, Katrin Hahn, Margot K. Davis, Nowell Fine, Björn Pilebro, Arti Gauvri Bhimjiyani, J. Gustav Smith
13:54-14:00	TRITON-CM: A phase 3 study to evaluate the efficacy and safety of nuresiran in patients with transthyretin amyloidosis with cardiomyopathy <u>Vincent Lau</u> , Marianna Fontana, Ahmad Masri, Mathew S. Maurer, John J. V. McMurray, Scott D. Solomon, Minzhao Liu, Patrick Y. Jay, Ronald M. Witteles
14:00-14:06	Early symptoms and medical history of patients with transthyretin amyloidosis cardiomyopathy: results from the multi-country OverTTuRe study J. Gustav Smith, Zhuang Tian, Katrin Hahn, Nowell Fine, <u>Björn Pilebro</u> , Jason Wright, Arti Gauvri Bhimjiyani, Krister Järbrink, Pablo García-Pavía
	GROUP 6 Patient's journey <i>Chair:</i> Otavio Rizzi Coelho Filho (Brazil)
13:30-13:36	Incidence, patient characteristics and clinical outcomes of amyloid polyneuropathy: an observational study in England using electronic health records Caroline Coats, Aron Buxton, Sivatharshini Ramalingam, Alex Simms, Kaushik Guha, Katharine McIntosh, David Gregory, Chris Morgan, Raj Thakkar, Ruchika Kohli, <u>He Gao</u> , Jil Billy Mamza, Julian D. Gillmore, Lisa Anderson
13:36-13:42	Understanding care pathways in cardiac amyloidosis: gaps and opportunities for early diagnosis and treatment <u>L.Y. Rekker</u> , M. Gallego-Llorente, N. Fine, T. Hagenacker, C. Whelan, J.R. Agostinho, P. van der Harst, M.I.F.J. Oerlemans
13:42-13:48	Clinical presentation and treatment landscape of patients with transthyretin amyloidosis with cardiomyopathy: a real-world study in five European countries and Japan Caroline Morbach, JinEndo, José González-Costello, Francesco Cappelli, <u>William E. Moody</u> , Elena Klimova, Gilbert Habib
13:48- 13:54	Quality standards for the diagnosis and management of ATTR and AL amyloidosis: a nominal group technique study <u>Giovanni Palladini</u> , David Gregory, Keith Dares, Dr Laura Obici, Dr William Moody, Carys Barton, Dr Catarina Falcão de Campos, Dr Maike Dohrn, Dr Nowell Fine, Dr Tomas Ripoll



PROGRAMME FOR DOCTORS

THURSDAY, 25 SEPTEMBER 2025

ROOM GALASSIA

13:54-14:00	Holistic clinical management of patients with transthyretin amyloidosis with cardiomyopathy Olga Azevedo, <u>Christine Chiti</u> , José González Costello, Keith Dares, Agnes Farrugia, Hiroaki Kitaoka, Olivier Lairez, Simone Longhi, Isabelle Lousada, Hansie Mathelier, Katharine McIntosh, Caroline Morbach, Paul Pozzo, Ronald Witteles, Julian Gillmore
14:00-14:06	Making information meaningful: mapping the amyloidosis patient information journey in the UK <u>Kate A Taylor</u> , Thirusha Lane, Sophie Randall, Darren Foard, Jennifer Pinney, Carol J Whelan
14:06-14:12	Clinician preferences for transthyretin amyloidosis treatment: Results from a discrete-choice experiment Francesco Cappelli, Angelique Smit, Christine Chiti, Christine Poulos, Richard Mellor, Cooper Bussberg, Matthew Doenges, David Danese, <u>Varun Kumar</u> , Johana Fajardo

THURSDAY, 25 SEPTEMBER 2025

ROOM CARLO 2

14.15-15.00	Transforming lives through innovation, research and partnerships in ATTR <i>This symposium is sponsored by ASTRAZENECA</i> <i>Chair: Pablo Garcia-Pavia (Spain)</i>
14.15-14.20	Welcome and Introduction Pablo Garcia-Pavia (Spain)
14.20-14.35	Transformative Treatment Options for ATTR Julian Gillmore (UK)
14.35-14.45	Expanding Research Through Real-World Evidence Isabel Conceição (Portugal)
14.45-14.55	Accelerating Care Pathways Through Healthcare Systems Partnerships Alberto Cipriani (Italy)
14.55-15.00	Questions and Answers and Closing Remarks Pablo Garcia-Pavia (Spain)
15.00-15.25	LECTURE From innovation to a better care: The Lombardy experience on rare diseases <i>Chair: Vittorio Bellotti (Italy)</i> Mario Melazzini (Italy)



PROGRAMME FOR DOCTORS

THURSDAY, 25 SEPTEMBER 2025

ROOM CARLO 2

15.25-16.40	SESSION 3 NEW PERSPECTIVES IN ATTR AMYLOIDOSIS TREATMENT <i>Chairs:</i> Thibaud Damy (France), Giovanni Palladini (Italy)
15.25-15.40	State of the art Olivier Lairez (France)
15.40-16.40	ORAL COMMUNICATIONS
15.40-15.52	Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy based on age: the HELIOS-B trial <u>Awais Sheikh</u> , Z. Michael Miao, Brian Claggett, Pablo Garcia-Pavia, Emre Aldinc, Julian Gillmore, Scott D. Solomon, Marianna Fontana
15.52-16.04	Efficacy and safety of nexiguran ziclumeran, an investigational CRISPR/Cas9 gene editing treatment: 24-month follow-up from a phase 1 study in patients with hereditary ATTR with polyneuropathy <u>Julian Gillmore</u> , Derek Smith, Jessica Kachadourian, David Lebwohl, Peijuan Zhu, Yuanxin Xu, Adia Leung, Alison Sonderfan, David E. Gutstein, Garen Manvelian, David Adams, Ed Gane, Jörg Täubel, Björn Pilebro, Andoni Echaniz-Laguna, Justin Kao, Safi Shahda, Alexandra Haagenzen, Liron Walsh
16.04-16.16	Timing of Mortality Benefit in Outcomes Trials in Transthyretin Amyloidosis <u>Scott D. Solomon</u> , Brian L. Claggett, Muthiah Vaduganathan, Matthew S. Maurer, Julian D. Gillmore, Marianna Fontana
16.16-16.28	Long-term efficacy and safety of eplontersen in patients with hereditary transthyretin amyloidosis with polyneuropathy: initial report from the open-label extension of the NEURO-TTTransform study John Berk, Teresa Coelho, Isabel Conceição, Morie Gertz, Sami Khella, Ahmad Masri, Mathew Maurer, Laura Obici, Jonas Wixner, Shiangtung Jung, T. Jesse Kwok, Pramod Reddy Patil, <u>Márcia Waddington Cruz</u>
16.28-16.40	HELIOS-B: 12-month results from the open-label extension period of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy <u>Pablo Garcia-Pavia</u> , R. Witteles, C. Morbach, D. Delgado, H. Kitaoka, M. S. Maurer, P. Van der Meer, A. Yilmaz, V. Algalarrondo, S. Solomon, F. Cappelli, K. L. Boyle, S. A. Eraly, L. Yang, J. Vest, M. Fontana
16.40-16.55	COFFEE BREAK



PROGRAMME FOR DOCTORS

THURSDAY, 25 SEPTEMBER 2025

ROOM CARLO 2

16.55-17.40	Treating ATTR amyloidosis as one disease by delivering rapid TTR knockdown with vutrisiran <i>This symposium is sponsored by ALNYLAM</i> <i>Chairs:</i> Chiara Briani (Italy), William Moody (UK)
16.55-17:00	Introduction Chiara Briani (Italy)
17.00-17.15	ATTR amyloidosis: one disease, multiple manifestations Chiara Briani (Italy), William Moody (UK)
17.15-17.30	The evolving data from the HELIOS trials and what it means for the treatment of patients with ATTR amyloidosis Chiara Briani (Italy), William Moody (UK)
17.30-17.40	Panel discussion on managing ATTR in its different manifestations Chiara Briani (Italy), William Moody (UK)
17.40-18.40	ROUND TABLE Gaps in Management of ATTR AMYLOIDOSIS in 2025 <i>Chairs:</i> Eugenia Cisneros Barroso (Spain), Christoph Roecken (Germany)
17.40-17.55	Drugs availability in different countries Márcia Waddington (Brazil)
17.55-18.10	How to build an amyloidosis network? Paolo Milani (Italy)
18.10-18.25	Evaluation of disease progression and response to therapy Isabel Conceição (Portugal)
18.25-18.40	Discussion



PROGRAMME FOR DOCTORS

FRIDAY, 26 SEPTEMBER 2025

ROOM CARLO 1

07.30-17.00 Secretariat Opening Hours and Registrations

08.30-09.15 **Precision Gene Editing in ATTR Amyloidosis: Driving CRISPR/Cas9 Innovations Forward**

This symposium is sponsored by INTELLIA

Chair: Scott. D. Solomon (USA)

8:30-08:35 **Welcome and Introductions**
Scott Solomon (USA)

08:35-08:45 **CRISPR Gene Editing Overview and Safety in ATTR Amyloidosis**
Julian Gillmore (UK)

08:45-08:55 **Where is CRISPR's Place in ATTR-CM?**
Marianna Fontana (UK)

08:55-09:05 **Where is CRISPR's Place in ATTR-PN?**
Marco Luigetti (Italy)

09:05-09:15 **Questions and Answers and Closing Remarks**

09.15-09.30 **BREAK**



JOINT PROGRAMME for DOCTORS and PATIENTS

FRIDAY, 26 SEPTEMBER 2025

ROOM CARLO 1

09.30-10.30	ROUND TABLE: BASIC AND CLINICAL RESEARCH IN AMYLOID DISEASES: WHERE ARE WE GOING? <i>This session is supported by BridgeBio</i> Vittorio Bellotti (Italy), Giovanni D'Alessio (Italy), Julian Gillmore (UK)
10.30-10.45	Holistic Management of ATTR: Addressing unmet needs <i>This symposium is sponsored by ALNYLAM</i> Chair: Christine Chiti (UK)
10.45-11.15	COFFEE BREAK
11.15-12.15	SESSION 1 CONTROVERSIES AND DEBATES: HOW WE MONITOR DISEASE PROGRESSION? Chairs: David Gregory (UK), Violaine Planté-Bordeneuve (France)
11.15-11.35	Use of guidelines: pros and cons Marianna Fontana (UK), Pablo Garcia-Pavia (Spain)
11.35-11.55	Patient reported outcome measures Hans Nienhuis (The Netherlands)
11.55-12.10	Discussion
12.10-12.30	The psychological burden of ATTR-CM: Challenges and coping strategies <i>This symposium is sponsored by BAYER</i> Chair: Martina Smorti (Italy)



JOINT PROGRAMME for DOCTORS and PATIENTS

FRIDAY, 26 SEPTEMBER 2025

ROOM CARLO 1

12.30-13.30	SESSION 2 SYMPTOMATIC MANAGEMENT OF ATTR AMYLOIDOSIS <i>Chairs:</i> Agnès Farrugia (France), Simone Longhi (Italy)
12.30-12.45	Urologic aspects Ricardo Pereira E Silva (Portugal)
12.45-13.00	Gastrointestinal aspects Jonas Wixner (Sweden)
13.00-13.15	Cardiac aspects Diana Bonderman (Austria)
13.15-13.30	Discussion
13.30-14.30	LUNCH
14.30-14.50	COLLABORATE Initiative (Empowering patients to address unmet needs of Adult-Onset Rare Disease through Shared Decision Making) <i>This symposium is sponsored by PFIZER</i> <i>Chair:</i> Anne Marie Carr (UK)
14.50-15.10	Presentation of Amylife Survey <i>Chair:</i> Giovanni Palladini (Italy) Thibaud Damy (France)
15.10-16.40	ROUND TABLE HOLISTIC APPROACH TO ATTR AMYLOIDOSIS: WHERE ARE WE GOING? <i>Chairs:</i> Keith Dares (Canada), Andoni Echaniz-Laguna (France)
15.10-15.25	Central nervous system manifestations Luisa Sousa (Portugal)
15.25-15.40	Eye involvement Angelo Minnella (Italy)
15.40-15.55	Targeted approaches: present and future Francesco Cappelli (Italy)
15.55-16.10	The role of geriatricians Manuel Sanchez (France)
16.10-16.25	Discussion
16.25-16.40	Conclusions Laura Obici (Italy), Giovanni D'Alessio (Italy)



GENERAL INFORMATION



CONGRESS VENUE

Grand Hotel Dino

Corso Garibaldi 20, Baveno (VB), Italy

<https://zaccherahotels.com/grand-hotel-dino/>

The Hotel is located in Baveno center, on the left shore of Lake Maggiore

LANGUAGE

The official language of the congress is English. Simultaneous translation will be provided (English, Italian, French and Spanish). Headset for the translation are available for free.

EXHIBITION

An exhibition will take place in the Congress Venue throughout the Meeting. It will be restricted to HCP, fellows and industry on Day 1 (25 September, 2025) while it will be open to all participants on Day 2 (26 September, 2025)

BADGE

Participants are strongly requested to wear their badge during all congress activities. The badge will admit to the scientific sessions, exhibition area, coffee breaks and lunches.

Wi-Fi

Free Congress Wi-Fi is available in the congress area.

ORGANIZING SECRETARIAT



STUDIO CONGRESSI S.r.l.

Viale della Libertà, 17 - 27100 Pavia (PV) - Italy

Tel. +39.0382.21424

Mobile +39 3387123939- +39 3518055151

info@studio-congressi.com

info@attr2025.com



GENERAL INFORMATION

OPENING TIMES

All times in CEST

DATE	REGISTRATION OPENING HOURS	SOCIAL EVENTS	EXHIBITION OPENING HOURS
Wednesday, 24 September 2025	17:00 - 19:00	Welcome Cocktail for all participants 19:30	
Thursday, 25 September 2025	07:30 - 18:30	Social Dinner 20:00	08:30-18:30 (HCP, fellows and industry only)
Friday, 26 September 2025	07:30 - 17:00		08:30-16:30 (all participants)

CUSTOMER SATISFACTION SURVEY & CERTIFICATE OF ATTENDANCE

You will receive a link to an online survey to evaluate the event the main congress services.
All participants will receive a link to download their certificate of attendance.

INSURANCE


Congress organizers cannot accept liability for personal injuries or for loss of or damage to property belonging to congress participants, either during or as a result of the congress.

PRIVACY POLICY

The information on the processing of personal data in accordance with European Regulation nr. 679 of 2016 has been inserted in the congress bags. Please consult the information sheet for full details

EXHIBITION AND VENUE FLOORPLAN

ATTR2025 - GRAND HOTEL DINO – CONGRESS AREA DETAIL



EXHIBITORS

1-2	BAYER
3	PFIZER
4	INTELLIA
5	ASTRAZENECA
6	ALNYLAM
7	PURPOSE PHARMA
8	BRIDGEBIO
9	CENTOGENE



SPONSORS & EXHIBITORS

We wish to express our sincere gratitude to our supporters for their generous contributions

